susceptibility of cyclin D1, but not of non-transgenic littermates, to pristane-induced lymphoma.
The age dependence makes this model somewhat cumbersome as a model in which to test new therapeutic approaches. Nonetheless, we have established a cell line derived from one of these lymphomas, which will prove useful for therapeutic testing. It is more likely that this multistep model will aid in developing a more complete understanding of the required steps in mantle cell lymphomagenesis and thus indicate potential new targets for therapy.
Absence of pathogenic mutations of the human telomerase RNA gene (hTERC) in patients with chronic myeloproliferative disorders Chronic myeloproliferative disorders (CMPDs) are acquired hematopoietic diseases, in which besides thrombotic and hemorrhagic complications, leukemic transformation can occur. Chronic myeloproliferative disorders are usually characterized by clonal proliferation of one or more cell lineages. However, a sizable proportion of patients with polycythemia vera (PV) and essential thrombocythemia (ET) show a polyclonal pattern of hematopoiesis. We have shown that whereas short telomere lengths are usually associated with clonal granulopoiesis, 1 no such correlation exists in patients with polyclonal granulopoietic phenotype. Interestingly, we have recently identified one ET patient, who carries an hTERC allele with a two-nucleotide deletion.
2 When hTERC RNA with this mutation (D389-390) was used to reconstitute telomerase enzymatic activity, it failed to do so, indicating that hTERC gene might directly be involved in telomere length regulation in some patients. We, therefore, attempt to validate this finding by sequencing PCR products encompassing the 451 bp of the hTERC gene and its flanking regulatory regions, including 100 bp of the proximal promoter region and 50 bp following the hTERC coding sequence, from granulocytes of 90 patients, who have been clinically diagnosed with CMPDs. The patients' samples were collected with proper informed consents using established protocols that were approved by the Institutional Review Boards at our institutions. Of these 90 patients, 28 were diagnosed with PV, 43 with ET and 19 with chronic idiopathic myelofibrosis (CIMF). Eighteen of the samples came from our previous study, 1 in which 15 have been associated with clonal granulopoiesis based on investigation of X chromosome inactivation patterns, and three with polyclonal granulopoietic phenotype. Except for four additional samples characterized as polyclonal, the clonality of the remaining samples was unknown.
We found that except for a G to A transition at position 58 in one of the hTERC alleles identified in one patient (see Figure 1) , who is an 85-year-old African-American female with CIMF, none of the other samples revealed any alteration in the gene. This G58A variation turns out to be a common sequence polymorphism (SNP) among African Americans. This natural sequence variation has been found to occur not only in patients with various hematological disorders (e.g., in 2/55 patients with myelodysplasia (MDS) 3 and 1/115 patient with Fanconi's anemia 4 ), but also in the general population of healthy African Americans (5/24 normal subjects in one study 3 and 8/101 in the other 5 ). This G58 nucleotide is not phylogenetically conserved in all of the known vertebrate's TERC RNAs and does not alter telomerase activity when tested in vitro. 6, 7 As this is the only sequence variation found in this cohort, we reason that mutation in hTERC gene in patients with PV, ET or other CMPDs rarely occurs and is unlikely related to telomere changes observed in some of these patients. We, therefore, speculate that the patient with the only other known hTERC variation described in our previous study (D389-390) might have been incorrectly diagnosed. 2 However, it remains possible that the observed shortened telomeres in PV or ET patients with clonal granulopoiesis might be caused by alterations in either the hTERT catalytic protein or in other telomere-or telomerase-associated protein factors. It is noteworthy that recent studies have reported a single acquired (somatic) mutation (Val617Phe) in the tyrosine kinase JAK2 gene in more than half of the patients with either ET or CIMF and in almost all patients with PV. 8 Although functional studies of JAK2 mutation confer several phenotypes that are consistent with the predicted hyperproliferative potential of cells of the CMPDs, they do not offer insights into the relationship between telomere length maintenance and disease pathogenesis. It is possible that other yet undefined genetic factors besides JAK2 may also play a role in CMPDs, in which each has clinical features that are distinct from the others. CD45 is the first prototypic receptor-like protein tyrosine phosphatase and is an essential regulator of signal transduction pathways in immune cells. 1 CD45 is one of the most abundant leukocyte cell surface glycoproteins and is considered to be expressed exclusively upon cells of the hematopoietic system. The expression of CD45 on mesenchymal stem cells (MSCs), progenitor cells exhibiting multilineage differentiation capacity and being able to generate fibroblasts, osteoblasts, adipocytes and chondrocytes, 2 has never been reported so far. Nevertheless, we had previously showed that expression of CD45 on bone marrow (BM)-derived and ex vivo-expanded MSCs can be detected on few specimens isolated from patients with hematological malignancies. The expression of CD45 was not only detected by flow cytometric analysis but was also demonstrated directly on 'fibroblast-like' cells by immunocytochemical study. The morphology of CD45 þ MSCs is similar to that of CD45 À MSCs and the multilineage differentiation potential of CD45 þ MSCs is well preserved. However, the expression of CD45 was lost after prolonged ex vivo culture. 3 
Figure 1
Electropherogram showing the heterozygous G58A (arrow) identified in a patient with chronic idiopathic myelofibrosis.
